Soleno Therapeutics (SLNO) Operating Leases (2021 - 2026)
Soleno Therapeutics (SLNO) posted quarterly Operating Leases of $3.2 million for Q1 2026, up 33.33% year-over-year from $2.4 million in Q1 2025, and up 62.93% quarter-over-quarter from $2.0 million in Q4 2025.
Soleno Therapeutics (SLNO) Operating Leases (2021 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Operating Leases for 6 consecutive years, with $3.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases rose 33.33% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $3.2 million (up 33.33% YoY), while the FY2025 annual figure was $2.0 million, down 21.44% from the prior year.
- Operating Leases rose to $3.2 million in Q1 2026 per SLNO's latest filing, from $2.0 million in the prior quarter.
- Across five years, Operating Leases topped out at $3.2 million in Q1 2026 and bottomed at $37000.0 in Q1 2024.
- Historically, Operating Leases has averaged $1.5 million across 5 years, with a median of $2.0 million in 2025.
- On a YoY basis, Operating Leases climbed as much as 6386.49% in 2025 and fell as far as 21.44% in 2025.
- Soleno Therapeutics' Operating Leases stood at $79000.0 in 2022, then climbed by 26.58% to $100000.0 in 2023, then jumped by 2400.0% to $2.5 million in 2024, then slipped by 21.44% to $2.0 million in 2025, then surged by 62.93% to $3.2 million in 2026.
- Business Quant data shows SLNO's Operating Leases at $3.2 million in Q1 2026, $2.0 million in Q4 2025, and $2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.20 Mn |
| Dec 31, 2025 | 1.96 Mn |
| Sep 30, 2025 | 2.11 Mn |
| Jun 30, 2025 | 2.20 Mn |
| Mar 31, 2025 | 2.40 Mn |
| Dec 31, 2024 | 2.50 Mn |
| Sep 30, 2024 | 2.60 Mn |
| Mar 31, 2024 | 37,000.00 |
| Dec 31, 2023 | 100,000.00 |
| Sep 30, 2023 | 214,000.00 |
| Jun 30, 2023 | 273,000.00 |
| Mar 31, 2022 | 79,000.00 |
| Dec 31, 2021 | 200,000.00 |
| Sep 30, 2021 | 274,000.00 |
| Jun 30, 2021 | 500,000.00 |